Is there a benefit from addiction to anti-VEGF therapy in patients with colorectal cancer?

Abstract

Studies carried out through the past two decades have evidenced that addition of bevacizumab to chemotherapy improves the efficacy both in first-line and second-line treatment in patients with metastatic colorectal cancer. Benefit of adding bevacizumab to second-line regimen after failing a bevacizumab-containing regimen, or aflibercept plus FOLFIRI) (irinotecan, 5-FU and leucovorin) after failing first-line oxaliplatin regimen with or without bevacizumab or regorafenib as a salvage therapy, do indicate the addiction to anti-vascular endothelial growth factor (VEGF) agents in these patients. This concept also lends some support from the NSABP C-08 adjuvant trial of colon cancer which showed very substantial improvement in time-to-recurrence for the one year of bevacizumab administration, but this benefit was quickly lost once the drug was stopped. The author reviews the data on anti-VEGF therapy in metastatic colorectal cancer.

• Authors: Muhammad Wasif Saif
• Journal: Anticancer research (Anticancer Res) Vol. 33 Issue 6 Pg. 2377-80 (Jun 2013) ISSN: 1791-7530 [Electronic] Greece
• PMID: 23749885 (Publication Type: Journal Article, Review)

Chemical References

• Angiogenesis Inhibitors
• Antibodies, Monoclonal, Humanized
• Phenylurea Compounds
• Pyridines
• Recombinant Fusion Proteins
• VEGFA protein, human
• Vascular Endothelial Growth Factor A
• aflibercept
• regorafenib
• Bevacizumab
• Receptors, Vascular Endothelial Growth Factor

Topics

• Angiogenesis Inhibitors (administration & dosage, therapeutic use)
• Antibodies, Monoclonal, Humanized (administration & dosage, therapeutic use)
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Bevacizumab
• Colorectal Neoplasms (drug therapy)
• Humans
• Phenylurea Compounds (therapeutic use)
• Pyridines (therapeutic use)
• Receptors, Vascular Endothelial Growth Factor (therapeutic use)
• Recombinant Fusion Proteins (therapeutic use)
• Treatment Outcome
• Vascular Endothelial Growth Factor A (antagonists & inhibitors)